150 related articles for article (PubMed ID: 22903817)
1. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG.
Isoda A; Higuchi T; Nakano S; Arisaka Y; Kaira K; Kamio T; Mawatari M; Matsumoto M; Sawamura M; Tsushima Y
Ann Nucl Med; 2012 Dec; 26(10):811-6. PubMed ID: 22903817
[TBL] [Abstract][Full Text] [Related]
2. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of ¹⁸F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with ¹⁸F-FDG PET/CT and MRI.
Kim M; Higuchi T; Arisaka Y; Achmad A; Tokue A; Tominaga H; Miyashita G; Miyazaki H; Negishi A; Yokoo S; Tsushima Y
Ann Nucl Med; 2013 Jun; 27(5):423-30. PubMed ID: 23436243
[TBL] [Abstract][Full Text] [Related]
5. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Nobusawa A; Kim M; Kaira K; Miyashita G; Negishi A; Oriuchi N; Higuchi T; Tsushima Y; Kanai Y; Yokoo S; Oyama T
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1692-700. PubMed ID: 23801167
[TBL] [Abstract][Full Text] [Related]
7. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry.
Miyashita G; Higuchi T; Oriuchi N; Arisaka Y; Hanaoka H; Tominaga H; Morita S; Miyakubo M; Ishikita T; Nakasone Y; Negishi A; Yokoo S; Endo K
Ann Nucl Med; 2010 Oct; 24(8):579-84. PubMed ID: 20652456
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
10. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
Kaira K; Higuchi T; Sunaga N; Arisaka Y; Hisada T; Tominaga H; Oriuchi N; Asao T; Tsushima Y; Yamada M
Anticancer Res; 2016 Dec; 36(12):6481-6490. PubMed ID: 27919971
[TBL] [Abstract][Full Text] [Related]
14. 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
Sohda M; Miyazaki T; Honjyo H; Hara K; Ozawa D; Sakai M; Yokobori T; Higuchi T; Tsushima Y; Kuwano H
Dig Surg; 2018; 35(5):383-388. PubMed ID: 29130979
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of sarcoidosis-lymphoma syndrome lesions: a case report on the use of two different positron emission tomography tracers.
Yudistiro R; Arisaka Y; Tokue A; Nakajima T
BMC Med Imaging; 2016 Jan; 16():1. PubMed ID: 26746426
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.
Tian M; Zhang H; Endo K
J Biomed Biotechnol; 2011; 2011():807929. PubMed ID: 21738405
[TBL] [Abstract][Full Text] [Related]
17. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
18.
Kim M; Higuchi T; Nakajima T; Andriana P; Hirasawa H; Tokue A; Kurihara J; Yokoo S; Tsushima Y
Oral Radiol; 2019 Sep; 35(3):308-314. PubMed ID: 30778900
[TBL] [Abstract][Full Text] [Related]
19. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
20. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
